uniQure N.V. (QURE) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
uniQure’s Phase I/II Huntington’s gene therapy trial showed a 75% slowing of progression, triggering a 250% price surge and near five-year high. Strong FDA alignment for BLA filing and robust capital provide near-term growth catalysts despite technical overbought conditions and dilution risk.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong Liquidity • Negative Cash Flow • High Burn Rate QURE has strong near-term liquidity and very high gross margins, but persistent losses, negative cash flow, and a rich valuation make it a speculative, high-risk investment.
Price Behavior
Key Price Behavior Insights: • Higher base • Sharp rebound • Near resistance Support Level: $17.45 to $17.60 Resistance Level: $18.03 to $18.04 QURE has been in a constructive uptrend over the last month, rebounding sharply from the mid/late-March low and now trading near resistance at $18.03–$18.04, but it needs to hold $17.45–$17.60 and break above $18.04 to confirm further upside.
Sentiment & News
Key News Insights: • Class action surge • Deadline pressure • FDA scrutiny UniQure (QURE) is facing a coordinated wave of securities class action notices over alleged misconduct, with investors repeatedly urged to act before the 2026-04-13 lead plaintiff deadline. #investor-alert
AI Summary
QURE should now be viewed less as a pure gene-therapy upside story and more as a high-risk, binary regulatory trade where AMT-130's science is promising but FDA pushback and a class-action overhang make approval timing, filing strategy, and legal defense the real drivers of value.
Description
uniQure N.V. is a gene therapy company developing treatments for genetic and other severe diseases. Its lead program, etranacogene dezaparvovec (AMT-061), is in the Phase III HOPE-B trial for hemophilia B, and the broader pipeline includes clinical and preclinical candidates targeting central nervous system and neuromuscular disorders such as Huntington’s disease, Parkinson’s disease, temporal lobe epilepsy, ALS and forms of Alzheimer’s, as well as earlier-stage hemophilia approaches. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 29 | Oct 6 | QURE | uniQure N.V. | uniQure’s Phase I/II Huntington’s gene therapy trial showed a 75% slowing of progression, triggering a 250% price surge and near five-year high. Strong FDA alignment for BLA filing and robust capital provide near-term growth catalysts despite technical overbought conditions and dilution risk. | Closed | -10.9% |